Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - vardenafil hydrochloride trihydrate, quantity: 5.926 mg (equivalent: vardenafil, qty 5 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; macrogol 400; hypromellose; titanium dioxide; iron oxide yellow; iron oxide red - levitra is indicated for the treatment of erectile dysfunction in adult males (inability to achieve or maintain penile erection sufficient for satisfactory sexual performance). levitra is not indicated for use by women.

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - vardenafil hydrochloride trihydrate (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil hydrochloride tablets are indicated for the treatment of erectile dysfunction. administration of vardenafil with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see clinical pharmacology (12.2)] . consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors, including vardenafil, may potentiate the hypotensive effects of nitrates. a suitable time interval following dosing of vardenafil for the safe administration of nitrates or nitric oxide donors has not been determined.  do not use vardenafil in patients who are using a gc stimulator, such as riociguat. pde5 inhibitors, including vardenafil may potentiate the hypotensive effects of gc stimulators. risk summary vardenafil is not indicated for use in females. there are no data with the use of vardenafil in pregnant women to inform any drug-associated risks. in animal reproduction studies conducted in pregnant rats and rabbits, no adverse deve

United States - English - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - vardenafil hydrochloride trihydrate (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil hydrochloride orally disintegrating tablets are indicated for the treatment of erectile dysfunction. administration of vardenafil hydrochloride orally disintegrating tablets with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see clinical pharmacology (12.2)] . consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors, including vardenafil hydrochloride orally disintegrating tablets, may potentiate the hypotensive effects of nitrates. a suitable time interval following vardenafil hydrochloride orally disintegrating tablets dosing for the safe administration of nitrates or nitric oxide donors has not been determined. do not use vardenafil hydrochloride orally disintegrating tablets in patients who are using a gc stimulator, such as riociguat. pde5 inhibitors, including vardenafil hydrochloride orally disintegrating tablets may potentiate the hypotensive effects of gc stimulators. risk summ

United States - English - NLM (National Library of Medicine)

alembic pharmaceuticals limited - vardenafil hydrochloride trihydrate (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil hydrochloride orally disintegrating tablets are indicated for the treatment of erectile dysfunction. administration of vardenafil hydrochloride orally disintegrating tablets with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see clinical pharmacology (12.2)] . consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors, including vardenafil hydrochloride orally disintegrating tablets, may potentiate the hypotensive effects of nitrates. a suitable time interval following vardenafil hydrochloride orally disintegrating tablets dosing for the safe administration of nitrates or nitric oxide donors has not been determined. do not use vardenafil hydrochloride orally disintegrating tablets in patients who are using a gc stimulator, such as riociguat. pde5 inhibitors, including vardenafil hydrochloride orally disintegrating tablets may potentiate the hypotensive effects of gc stimulators. risk summ

United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - vardenafil hydrochloride trihydrate (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil hydrochloride tablets are indicated for the treatment of erectile dysfunction. administration of vardenafil with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see clinical pharmacology ( 12.2)] . consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors, including vardenafil, may potentiate the hypotensive effects of nitrates. a suitable time interval following dosing of vardenafil for the safe administration of nitrates or nitric oxide donors has not been determined.  do not use vardenafil in patients who are using a gc stimulator, such as riociguat. pde5 inhibitors, including vardenafil may potentiate the hypotensive effects of gc stimulators. risk summary vardenafil is not indicated for use in females. there are no data with the use of vardenafil in pregnant women to inform any drug-associated risks. in animal reproduction studies conducted in pregnant rats and rabbits,

United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - vardenafil hydrochloride trihydrate (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil hydrochloride tablets are indicated for the treatment of erectile dysfunction. administration of vardenafil with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see clinical pharmacology (12.2)] . consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors, including vardenafil, may potentiate the hypotensive effects of nitrates. a suitable time interval following dosing of vardenafil for the safe administration of nitrates or nitric oxide donors has not been determined.  do not use vardenafil in patients who are using a gc stimulator, such as riociguat. pde5 inhibitors, including vardenafil may potentiate the hypotensive effects of gc stimulators. pregnancy category b vardenafil is not indicated for use in women. there are no studies of vardenafil use in pregnant women. no evidence of specific potential for teratogenicity, embryotoxicity or fetotoxicity was observed in rats and rabbits that

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - vardenafil hydrochloride trihydrate - film-coated tablet - 10 milligram(s) - drugs used in erectile dysfunction; vardenafil

Canada - English - Health Canada

mylan pharmaceuticals ulc - vardenafil (vardenafil hydrochloride trihydrate) - tablet - 5mg - vardenafil (vardenafil hydrochloride trihydrate) 5mg - phosphodiesterase type 5 inhibitors

Canada - English - Health Canada

mylan pharmaceuticals ulc - vardenafil (vardenafil hydrochloride trihydrate) - tablet - 10mg - vardenafil (vardenafil hydrochloride trihydrate) 10mg - phosphodiesterase type 5 inhibitors

Canada - English - Health Canada

mylan pharmaceuticals ulc - vardenafil (vardenafil hydrochloride trihydrate) - tablet - 20mg - vardenafil (vardenafil hydrochloride trihydrate) 20mg - phosphodiesterase type 5 inhibitors